![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication April 29, 2004.
Revised August 19, 2004.
Accepted for publication August 19, 2004.
The catestatin fragment of chromogranin A is an endogenous inhibitor of nicotinic cholinergic transmission, functioning in negative-feedback control of catecholamine secretion. We explored naturally occurring polymorphism in the amino acid sequence of catestatin. Three human variants were identified: Gly364Ser, Pro370Leu, and Arg374Gln. Variants were tested for ability to inhibit four nicotinic processes. The rank order of potency for inhibition of catecholamine secretion was Pro370Leu > wild-type > Gly364Ser > Arg374Gln. Decrease in potency was paralleled by decline in Hill slope, suggesting that negative cooperativity at ascending dose might underlie loss of potency. Several lines of evidence indicated that each variant acted as a nicotinic antagonist: potency to inhibit secretion paralleled inhibition of agonist-triggered 22Na+ uptake (r=0.986); variants inhibited secretion with similar potency when triggered by several nicotinic agonists, though not by agents utilizing other secretory pathways or bypassing the nicotinic receptor; and blockade of secretion was non-competitive with agonist. Variants also inhibited desensitization of secretion after prior agonist exposure, and stimulation of secretory protein biosynthesis by agonist. Rank order of variant inhibitory potency for all four nicotinic processes was identical (Pro370Leu > wild-type > Gly364Ser > Arg374Gln), suggesting mediation by similar combinations of receptor 
/
subunits, and that crucial catestatin residues are likely to be identical across the four processes. When catestatin variants were mixed in likely heterozygotic 50:50 combinations, the inhibitory curve was left-shifted onto that of the more potent variant in the combination, suggesting phenotypic dominance. The results have quantitative implications for inter-individual variations in human nicotinic signaling.
Key words:
Neuropeptides, Nicotinic cholinergic, Structure-activity relationships and modeling, Regulation of gene expression, Structure/function/mechanism, Exocytosis
This article has been cited by other articles:
|
|
 |
|
  N. R. Mahapatra Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure Cardiovasc Res, December 1, 2008; 80(3): 330 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Angelone, A. M. Quintieri, B. K. Brar, P. T. Limchaiyawat, B. Tota, S. K. Mahata, and M. C. Cerra The Antihypertensive Chromogranin A Peptide Catestatin Acts as a Novel Endocrine/Paracrine Modulator of Cardiac Inotropism and Lusitropism Endocrinology, October 1, 2008; 149(10): 4780 - 4793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. O'Connor, G. Zhu, F. Rao, L. Taupenot, M. M. Fung, M. Das, S. K. Mahata, M. Mahata, L. Wang, K. Zhang, et al. Heritability and Genome-Wide Linkage in US and Australian Twins Identify Novel Genomic Regions Controlling Chromogranin A: Implications for Secretion and Blood Pressure Circulation, July 15, 2008; 118(3): 247 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mazza, A. Gattuso, C. Mannarino, B. K. Brar, S. F. Barbieri, B. Tota, and S. K. Mahata Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H113 - H122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Biswas, S. M. Vaingankar, M. Mahata, M. Das, J. R. Gayen, L. Taupenot, J. W. Torpey, D. T. O'Connor, and S. K. Mahata Proteolytic Cleavage of Human Chromogranin A Containing Naturally Occurring Catestatin Variants: Differential Processing at Catestatin Region by Plasmin Endocrinology, February 1, 2008; 149(2): 749 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rao, J. Wessel, G. Wen, L. Zhang, B. K. Rana, B. P. Kennedy, T. A. Greenwood, R. M. Salem, Y. Chen, S. Khandrika, et al. Renal Albumin Excretion: Twin Studies Identify Influences of Heredity, Environment, and Adrenergic Pathway Polymorphism Hypertension, May 1, 2007; 49(5): 1015 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Hendy, T. Li, M. Girard, R. C. Feldstein, S. Mulay, R. Desjardins, R. Day, A. C. Karaplis, M. L. Tremblay, and L. Canaff Targeted Ablation of the Chromogranin A (Chga) Gene: Normal Neuroendocrine Dense-Core Secretory Granules and Increased Expression of Other Granins Mol. Endocrinol., August 1, 2006; 20(8): 1935 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Greenwood, F. Rao, M. Stridsberg, N. R. Mahapatra, M. Mahata, E. O. Lillie, S. K. Mahata, L. Taupenot, N. J. Schork, and D. T. O'Connor Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion Physiol Genomics, May 16, 2006; 25(3): 470 - 479. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
